Search results for "CD8-Positive T-Lymphocyte"

showing 10 items of 294 documents

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

2017

Background: The effect of dimethyl fumarate (DMF) on circulating lymphocyte subsets and their contribution as predictors of clinical efficacy have not yet been investigated in multiple sclerosis (MS). Objective: To evaluate lymphocytes and lymphocyte subsets (analyzed 6 months after DMF start) in MS patients with and without disease activity after 1 year of treatment in a retrospective study. Methods: Peripheral blood lymphocyte subsets were analyzed by flow cytometry. Untreated MS patients ( n = 40) were compared to those 6 months after onset of DMF treatment ( n = 51). Clinical and magnetic resonance imaging (MRI) disease activity of DMF-treated patients were assessed in the first year un…

AdultMale0301 basic medicineTreatment responseMultiple SclerosisAdolescentDimethyl FumarateAntigens CD19CD4-CD8 RatioCD8-Positive T-LymphocytesPharmacologyStatistics NonparametricReduction (complexity)Young Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningLymphopeniamedicineHumansCytotoxic T cellLongitudinal StudiesLymphocyte CountClinical efficacyRetrospective StudiesB-LymphocytesDimethyl fumarateChemistrybusiness.industryMultiple sclerosisMiddle AgedFlow Cytometrymedicine.diseaseMagnetic Resonance ImagingCross-Sectional StudiesTreatment Outcome030104 developmental biologyROC CurveNeurologyDisease ProgressionFemaleNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgeryFollow-Up StudiesLymphocyte subsetsMultiple Sclerosis Journal
researchProduct

Impact of antiretroviral and tuberculosis therapies on CD4 + and CD8 + HIV/M. tuberculosis-specific T-cell in co-infected subjects

2018

Abstract Background Human Immunodeficiency Virus (HIV) infection is a risk factor for tuberculosis (TB). Antiretroviral therapy (ART) changed HIV clinical management but it is still unclear how pre-existing HIV/Mycobacterium tuberculosis (Mtb)-specific CD4+ and CD8+ T-cells are restored. Aim to evaluate the impact of ART and TB therapies on the functional and phenotypic profile of Mtb-specific antigen-response of CD4+ and CD8+ T-cells in prospectively enrolled HIV-TB co-infected patients. Methods ART-naive HIV-infected patients, with or without active TB or latent TB infection (LTBI), were enrolled before and after starting ART and TB therapies. Peripheral blood mononuclear cells (PBMC) wer…

AdultMale0301 basic medicineTuberculosisTuberculosiImmunologyT-Lymphocyte SubsetMycobacterium tuberculosiPeripheral blood mononuclear cellMycobacterium tuberculosisAntitubercular Agent03 medical and health sciences0302 clinical medicineAntigenImmunology and AllergyMedicineHIV Infection030212 general & internal medicineCD8 + T-cellsRisk factorCytokineHIV AntigenAntigens BacterialbiologyCoinfectionbusiness.industryHIVvirus diseasesCD8-Positive T-Lymphocytebacterial infections and mycosesmedicine.diseasebiology.organism_classification030104 developmental biologyHIV AntigensCD4-Positive T-LymphocyteCD4 + T-cellsTuberculosis therapyImmunologyLeukocytes MononuclearCoinfectionAnti-Retroviral AgentFemalebusinessARTCD8HumanImmunology Letters
researchProduct

Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8+T cells that are associated with protection from and control of …

2015

Background The functional profile of cytomegalovirus (CMV)-specific CD8+ T cells that associate with protection from and control of CMV DNAemia in allogeneic stem cell transplant (allo-SCT) recipients remains incompletely characterized. Methods We enumerated pp65 and immediate early (IE)-1-specific CD8+ T cells expressing interferon-gamma, tumor necrosis factor-alpha, and CD107a, by flow cytometry in 94 patients at days +30 and +60 after allo-SCT. Results Fifty of 94 patients had CMV DNAemia within the first 100 days after transplant. CMV-specific CD8+ T-cell responses (of any functional type) were more likely to be detected in patients who did not display CMV DNAemia than in those who did …

AdultMaleAdolescentCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesLower riskFlow cytometryCohort StudiesViral Matrix ProteinsInterferon-gammaYoung AdultmedicineHumansTransplantation HomologousCytotoxic T cellAgedTransplantationmedicine.diagnostic_testTumor Necrosis Factor-alphabusiness.industryvirus diseasesMiddle AgedPhosphoproteinsmedicine.diseaseVirologyTransplantationInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleTumor necrosis factor alphaStem cellbusinessCD8Stem Cell TransplantationTransplant Infectious Disease
researchProduct

Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infec…

2015

The role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and that of antibodies neutralizing virus epithelial infection (AbNEI) in the control of CMV DNAemia were investigated in 39 CMV-seropositive allogeneic stem-cell transplant (Allo-SCT) recipients with (n = 24) or without (n = 15) CMV DNAemia. AbNEI levels were monitored prospectively by means of a neutralization assay employing retinal epithelial cells (ARPE-19) and the recombinant CMV strain BADrUL131-Y4. Quantification of CMV-specific polyfunctional CD8+ T-cells (expressing two or three of the following markers: IFN-γγ, TNF-α and CD107a) in whole blood was performed by flow cytometry for intracellular cytokine staining…

AdultMaleCellular immunityCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesAntibodies ViralEpitheliumVirusVirologymedicineHumansTransplantation HomologousCytotoxic T cellProspective StudiesViremiaAgedbiologyHematopoietic Stem Cell Transplantationvirus diseasesMiddle Agedmedicine.diseaseAntibodies NeutralizingVirologyTransplantationViral replicationCytomegalovirus InfectionsImmunologybiology.proteinFemaleAntibodyCD8Journal of General Virology
researchProduct

Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+T cells from individuals immunized with recombinant hepatitis B surfa…

2002

SUMMARYRecent studies have suggested that vaccination induces alterations in the T cell receptor (TCR) repertoire. We investigate the diversity of the TCR repertoire after immunization with a recombinant hepatitis B surface vaccine in seven healthy subjects in CD8+ T cells in peripheral blood lymphocytes. Cellular immune responses were monitored over time by sorting CD8 T cells followed by TCR-VA and -VB complementarity determining region 3 (CDR3) analysis. Frequency of individual VB families was determined by flow cytometry. TCR-VA/VB repertoires obtained from CD8+ T cells drawn after vaccination were compared to the TCR repertoire determined prior to vaccination. Monoclonal TCR transcript…

AdultMaleDNA ComplementaryReceptors Antigen T-Cell alpha-betaT cellMolecular Sequence DataImmunologychemical and pharmacologic phenomenaCD8-Positive T-LymphocytesBiologyEpitopeInterleukin 21AntigenAntibody SpecificityClinical StudiesmedicineHumansImmunology and AllergyCytotoxic T cellHepatitis B VaccinesAmino Acid SequenceLongitudinal StudiesGene Rearrangement beta-Chain T-Cell Antigen ReceptorImmunity CellularVaccines SyntheticBase SequenceT-cell receptorAntibodies Monoclonalhemic and immune systemsT lymphocyteMiddle AgedComplementarity Determining RegionsVirologymedicine.anatomical_structureImmunologyFemaleImmunizationGene Rearrangement alpha-Chain T-Cell Antigen ReceptorCD8Clinical and Experimental Immunology
researchProduct

A New Clinical and Immunovirological Score for Predicting the Risk of Late Severe Infection in Solid Organ Transplant Recipients: The CLIV Score

2020

Abstract Background We aimed at constructing a composite score based on Epstein-Barr virus DNAemia (EBVd) and simple clinical and immunological parameters to predict late severe infection (LI) beyond month 6 in solid organ transplantation (SOT) recipients. Methods Kidney and liver transplant recipients between May 2014 and August 2016 at 4 participating centers were included. Serum immunoglobulins and complement factors, peripheral blood lymphocyte subpopulations, and whole blood EBVd were determined at months 1, 3, and 6. Cox regression analyses were performed to generate a weighted score for the prediction of LI. Results Overall, 309 SOT recipients were followed-up for a median of 1000 da…

AdultMaleEpstein-Barr Virus InfectionsHerpesvirus 4 Humanmedicine.medical_specialtymedicine.medical_treatmentCD8-Positive T-LymphocytesOpportunistic Infections030230 surgeryLiver transplantationOrgan transplantationLeukocyte Count03 medical and health sciencesPostoperative Complications0302 clinical medicineInterquartile rangeInternal medicinemedicineHumansImmunology and AllergyAgedImmunosuppression TherapyReceiver operating characteristicProportional hazards modelbusiness.industryOrgan TransplantationMiddle AgedConfidence intervalTransplantationInfectious DiseasesROC CurvePeripheral blood lymphocyteDNA ViralMultivariate AnalysisFemale030211 gastroenterology & hepatologybusinessThe Journal of Infectious Diseases
researchProduct

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 + T Cells To Predict CMV DNAemia Clearance in …

2014

ABSTRACT It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8 + T cells) appeared to perform better for this purpose.

AdultMaleGanciclovirvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesClinical TherapeuticsViral Matrix ProteinsInterferon-gammamedicineHumansValganciclovirCytotoxic T cellPharmacology (medical)GanciclovirMultiple myelomaPharmacologybusiness.industryLymphoma Non-HodgkinAnemia Aplasticvirus diseasesValganciclovirMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPhosphoproteinsmedicine.diseaseTransplant RecipientsLeukemia Myeloid AcuteLeukemiaInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellMultiple MyelomabusinessCD8Stem Cell Transplantationmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia

2013

The pathogenic role of B cells in immune thrombocytopenia (ITP) has justified the therapeutic use of anti-CD20 antibodies such as rituximab (RTX). However, 60% of ITP patients do not respond to RTX. To decipher the mechanisms implicated in the failure of RTX, and because the spleen plays a well-recognized role in ITP pathogenesis, 12 spleens from ITP patients who had been nonresponders to RTX therapy were compared with 11 spleens from RTX-untreated ITP patients and 9 controls. We here demonstrate that in RTX-nonresponder ITP patients, preferential Th1 and Tc1 T lymphocyte polarizations occur, associated with an increase in splenic effector memory CD8(+) T-cell frequency. Moreover, in the RT…

AdultMaleImmunologyDrug ResistanceSpleenCD8-Positive T-LymphocytesLymphocyte ActivationReal-Time Polymerase Chain ReactionBiochemistryPathogenesisAntibodies Monoclonal Murine-DerivedYoung Adultimmune system diseaseshemic and lymphatic diseasesmedicineHumansImmunologic FactorsCytotoxic T cellAgedAged 80 and overPurpura Thrombocytopenic Idiopathicbiologybusiness.industryCell BiologyHematologyT lymphocyteMiddle AgedImmunohistochemistrymedicine.anatomical_structureImmunologyMonoclonalbiology.proteinFemaleRituximabAntibodyRituximabbusinessSpleenCD8medicine.drugBlood
researchProduct

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some M…

1999

Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to cancer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma. The DCs were pulsed with Mage-3A1 tumor peptide and a recall antigen, tetanus toxoid or tuberculin. 11 far advanced stage IV melanoma patients, who were progressive despite standard chemotherapy, received five DC vaccinations at 14-d intervals. The first three vaccinations were administered into the skin, 3 × 106 DCs each subcutaneously and intradermally, followed by two intravenous injections of 6 × 106 and 12 × 106 DCs, respectively. Only minor (less than or equal to grade II) side effects were observed. Immunity t…

AdultMaleLung NeoplasmsImmunologyCD8-Positive T-LymphocytesTuberculincytotoxic T lymphocytesCancer VaccinesMonocytesLymphocytes Tumor-InfiltratingImmune systemAntigenAntigens NeoplasmTetanus ToxoidmelanomaHumansImmunology and AllergyMedicineCytotoxic T celldendritic cellsNeoplasm MetastasisLymph nodeImmunization ScheduleAgedNeoplasm Stagingactive immunotherapybusiness.industryMelanomaDendritic cellMiddle Agedvaccinationmedicine.diseaseTumor antigenNeoplasm Proteinsmedicine.anatomical_structureImmunologyFemaleOriginal ArticlebusinessCD8T-Lymphocytes CytotoxicJournal of Experimental Medicine
researchProduct

Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients

2015

Melanomas are aggressive skin tumors characterized by high metastatic potential. Our previous results indicate that Natural Killer (NK) cells may control growth of melanoma. The main defect of blood NK cells was a decreased expression of activating NCR1/NKp46 receptor and a positive correlation of NKp46 expression with disease outcome in stage IV melanoma patients was found. In addition, in stage III melanoma patients, we identified a new subset of mature NK cells in macro-metastatic Lymph nodes (LN). In the present studies, we evaluated the numbers of NK cells infiltrating primary cutaneous melanoma and analyzed immune cell subsets in a series of sentinel lymph nodes (SLN). First, we show …

AdultMalePathologymedicine.medical_specialtyCD34lcsh:MedicineCD8-Positive T-LymphocytesBiologyTumor MicroenvironmentmedicineHumansCytotoxic T celllcsh:ScienceMelanomaAgedNeoplasm StagingAged 80 and overTumor microenvironmentMultidisciplinarySentinel Lymph Node BiopsyMacrophagesMelanomalcsh:REndothelial CellsMiddle Agedmedicine.diseaseAntigens Differentiation3. Good healthKiller Cells NaturalGranzyme BCutaneous melanomalcsh:QFemaleLymphCD8Research ArticlePLOS ONE
researchProduct